Market Overview

UPDATE: Stifel Nicolaus Raises PT to $85 on Gilead Sciences on HCV Data

Share:
Related GILD
Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock
Jim Cramer Advises His Viewers On Seagate, Centurylink And Gilead
Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' (Investor's Business Daily)

Stifel Nicolaus maintained its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $80 to $85.

Stifel Nicolaus commented, "Twelve week sofosbuvir plus BMY's NS5a daclatasvir treatment achieved an impressive SVR4 of 98% in treatment naïve genotype 1 patients, and the same combo with ribavirin achieved a 95% SVR4. … On the Abbott investor call held last night, ABT management indicated that they expect data from its six-trial registrational program in 2013 with market launch in 2015."

Gilead Sciences closed at $73.93 on Monday.

Latest Ratings for GILD

DateFirmActionFromTo
Jul 2017JefferiesAssumesHold
Jun 2017Deutsche BankInitiates Coverage OnBuy
Mar 2017UBSDowngradesBuyNeutral

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!